DBV Technologies Earnings
The next earnings date for DBV Technologies is October 27, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of DBV Technologies Earnings
| 10/27/2026 | $-0.60 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
DBV Technologies Earnings: Historical
| 07/16/2026 | After Market | $-0.60 | -400.00% |
| 04/30/2026 | After Market | $-0.09 | 25.00% |
| 03/27/2026 | --- | $-0.20 | -5.73% |
| 10/28/2025 | After Market | $-0.21 | 27.59% |
| 07/29/2025 | After Market | $-0.27 | -68.75% |
| 04/30/2025 | After Market | $-0.23 | -4.55% |
| 03/05/2025 | Before Market | $-0.21 | -1.24% |
| 11/06/2024 | After Market | $-1.49 | 9.15% |
| 07/30/2024 | After Market | $-1.57 | 40.75% |
| 05/07/2024 | After Market | $-5.20 | -152.43% |
More About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
“DBV Technologies Earnings” Can Refer to the DBV Technologies Earnings Date
Some people say “DBV Technologies earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my DBV Technologies position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning DBV Technologies Stock on the Earnings Date
If you own DBV Technologies stock (DBVT) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for DBV Technologies might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading DBV Technologies shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More DBV Technologies Earnings
You can contact us any time if you would like to ask questions about DBV Technologies earnings or anything else related to the stock market.